Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665375 | 0.89 | SMN1; SMN2 (0.75) | SMN1; SMN2ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL10337390 | 0.85 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1TDP1TSHRSPHK2 | |
| SCHEMBL143771 | 0.85 | — | — | |
| Water SCHEMBL27814314 | 0.83 | — | — | |
| SCHEMBL14205384 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL4654896 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL16004916 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL16004796 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL23919095 | 0.81 | TSHR (0.55) | SMN1; SMN2ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL3371973 | 0.81 | TSHR (0.52) | SMN1; SMN2ALDH1A1TDP1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135319-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20140135319-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| WO-2012080236-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135319-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TK1, CDK1, CDKL1 | SMN1; SMN2 1787/4885ALDH1A1 2008/4885TDP1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.